Lv1
50 积分 2023-10-08 加入
Renal and Multiorgan Safety of177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
12天前
已完结
Long-Term Nephrotoxicity of177Lu-PSMA Radioligand Therapy
19天前
已完结
前列腺癌PSMA PET显像临床应用中国专家共识(2025版)
1个月前
已完结
Circulating Tumor DNA Genomic Profiling in 223 Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study
1个月前
已完结
Clinical Outcomes of177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
1个月前
已关闭
Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer
1个月前
已完结
Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer
1个月前
已完结
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
1个月前
已完结
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
1个月前
已完结
A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer
1个月前
已完结
皖公网安备34019202002308
